Cargando…

Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease

BACKGROUND: The adverse effects of the phosphodiesterase-4 inhibitor roflumilast, appear to be more frequent in clinical practice than what was observed in chronic obstructive pulmonary disease (COPD) clinical trials. Thus, we designed this study to determine whether adverse effects could be reduced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Hyunjung, Shin, Ji Young, Park, Kyu Ree, Shin, Jae Ouk, Song, Kyoung-hwan, Park, Joonhyung, Park, Jeong Woong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Tuberculosis and Respiratory Diseases 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620324/ https://www.ncbi.nlm.nih.gov/pubmed/26508918 http://dx.doi.org/10.4046/trd.2015.78.4.321

Ejemplares similares

Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
por: Park, Tai Sun, et al.
Publicado: (2019)

Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
por: Kim, Kyung Hoon, et al.
Publicado: (2017)

The Phosphodiesterase 4 Inhibitor Roflumilast Protects against Cigarette Smoke Extract-Induced Mitophagy-Dependent Cell Death in Epithelial Cells
por: Kyung, Sun Young, et al.
Publicado: (2018)

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
por: Facius, Axel, et al.
Publicado: (2018)

Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
por: Watz, Henrik, et al.
Publicado: (2018)

Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients
por: Liu, Dong-yang, et al.
Publicado: (2018)

Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease
por: Wagner, Linda Timm, et al.
Publicado: (2005)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

Prasugrel-Based De-Escalation in Patients With Acute Coronary Syndrome According to Renal Function
por: Yun, Jun Pil, et al.
Publicado: (2023)

Effectiveness of Roflumilast in Treating Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
por: Naseem, Sumbal, et al.
Publicado: (2022)

Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B
por: Eshghi, Peyman, et al.
Publicado: (2017)

Study on the Improvement of Health and Nutrition Status After a 12-week Protein-Rich Supplementation Regimen in Children and Adolescents With Brain Lesions Disorder
por: Yoon, Hyeji, et al.
Publicado: (2022)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

A Retrospective Study Investigating Risks of Acute Respiratory Distress Syndrome and Mortality Following Human Metapneumovirus Infection in Hospitalized Adults
por: Hwang, Hyunjung, et al.
Publicado: (2017)

Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer
por: Bertholet, Jenny, et al.
Publicado: (2019)

Molecular pattern of a decrease in the rewarding effect of cocaine after an escalating-dose drug regimen
por: Kołosowska, Karolina, et al.
Publicado: (2022)

Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2015)

Butyrate modulates mucin secretion and bacterial adherence in LoVo cells via MAPK signaling
por: Jung, Tae-Hwan, et al.
Publicado: (2022)

Randomized clinical trial comparing fixed-time split dosing and split dosing of oral Picosulfate regimen for bowel preparation
por: Jun, Jae Hyuck, et al.
Publicado: (2017)

New therapeutic options in the management of COPD – focus on roflumilast
por: Antoniu, Sabina Antonela
Publicado: (2011)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

Roflumilast partially reverses smoke-induced mucociliary dysfunction
por: Schmid, Andreas, et al.
Publicado: (2015)

Does roflumilast induce phagocytic activity in COPD patients?
por: Ghosh, Baishakhi, et al.
Publicado: (2015)

Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
por: Zhang, Xiaoli, et al.
Publicado: (2018)

Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy
por: Ring, Hans Christian, et al.
Publicado: (2022)

Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
por: Long, Millie D., et al.
Publicado: (2022)

Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease
por: Fu, Alex Z, et al.
Publicado: (2015)

Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer
por: Park, Se Hoon, et al.
Publicado: (2005)

Efficacy of Dose-Escalated Radiotherapy for Recurrent Colorectal Cancer
por: Jo, Sunmi, et al.
Publicado: (2016)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Adherence and Associated Factors of Treatment Regimen in Drug-Susceptible Tuberculosis Patients
por: Bea, Sungho, et al.
Publicado: (2021)

Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
por: Kim, Do Young, et al.
Publicado: (2022)

Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations
por: Alispahic, Imane Achir, et al.
Publicado: (2020)

The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials
por: Jafari Andarian, Saeideh, et al.
Publicado: (2016)

Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers
por: Huang, Jie, et al.
Publicado: (2018)

Safety and Efficacy of Low-Volume Preparation in the Elderly: Oral Sulfate Solution on the Day before and Split-Dose Regimens (SEE SAFE) Study
por: Kwak, Min Seob, et al.
Publicado: (2019)

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
por: Gauvreau, Gail M, et al.
Publicado: (2011)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway
por: Xu, Wan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_in11vgjgfbkrvqc0h3sjnh4lk5